Company Profile
Acrivon Therapeutics Stock Price, News & Analysis
- Ticker:
- ACRV
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Acrivon Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
1.63 USD (+3.16%)
Close
Last updated: June 23, 2026 at 00:00
69.77M USD
Market cap
Why the stock is moving
ACRV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Acrivon Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Acrivon Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Acrivon Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Source: Acrivon Therapeutics
- 02
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Source: Acrivon Therapeutics
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics (ACRV) most recently closed at 1.63 USD, a +3.16% move versus the previous session.
What is the market cap of Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics currently has a market capitalization of 69.77M USD on BioPharmSignal.
What does Acrivon Therapeutics do?
Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ACRV stock listed?
Acrivon Therapeutics (ACRV) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Acrivon Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Acrivon?
Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Acrivon Therapeutics targeting with Acrivon?
Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.